Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alitretinoin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Alitretinoin | DRUG | - |
Inclusion Criteria Patients must have: * HIV positive status and histologic confirmation of KS. * CD4 count \> 200 mm3 (required of one-half of patients). * Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting criteria for "indicator" lesions. * Acceptable organ syste...
Alitretinoin is an investigational small molecule being studied for the treatment of AIDS-related Kaposi's sarcoma. It is in Phase 2 clinical development and has been evaluated in a completed clinical trial involving patients with this condition.
Alitretinoin is a retinoid that works by binding to and activating retinoic acid receptors, which are nuclear receptors that regulate gene expression involved in cell growth and differentiation. This mechanism is being explored in the context of Kaposi's sarcoma.
Alitretinoin is being developed by Ligand Pharmaceuticals Incorporated, a biopharmaceutical company listed on the NASDAQ under the ticker symbol LGND.
Alitretinoin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial has been completed to evaluate its safety and efficacy.
Alitretinoin has been studied in one completed Phase 2 clinical trial, identified as NCT00002188, titled 'A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.' The trial enrolled 27 participants and was not randomized or double-blinded.
Yes, Alitretinoin is also known as ALRT1057. The clinical trial NCT00002188 refers to the drug as ALRT1057, and it is the same investigational agent being developed by Ligand Pharmaceuticals.